Major influence of renal function on hyperlipidemia after living donor liver transplantation

Table 2 Comparison between patients with and without early renal dysfunction (means ± SD)

	ERD(n = 16)	Non-ERD(n = 99)	P value
Pre-transplant
MELD	30.1 ± 11.7	19.5 ± 9.4	< 0.001
Total bilirubin (mg/dL)	15.2 (1.8-29.8)	13.6 (0.8-36.5)	NS
International normalized ratio	1.6 ± 0.9	1.4 ± 0.7	NS
Serum creatinine (mg/dL)	2.2 (0.7-4.0)	0.8 (0.5-4.5)	< 0.001
Renal insufficiency > 15 d n (%)	11 (68.8)	15 (15.2)	< 0.001
Hemodialysis n (%)	11 (68.8)	5 (5.1)	< 0.001
Serum triglyceride (mg/dL)	77.7 ± 58.4	77.7 ± 62.7	NS
Serum cholesterol (mg/dL)	92.7 ± 42.9	119.3 ± 55.6	NS
Post-transplant
Serum creatinine (mg/dL)
At month 1	1.4 (0.6-2.8)	0.7 (0.2-1.2)	< 0.001
At month 3	1.0 (0.6-3.0)	0.7 (0.3-1.3)	0.008
At month 6	1.1 (0.6-4.1)	0.7 (0.3-1.5)	< 0.001
Total bilirubin (mg/dL)
At month 1	1.3 (0.4-4.3)	1.1 (0.3-5.8)	NS
At month 3	0.6 (0.2-2.5)	0.7 (0.3-2.5)	NS
At month 6	0.6 (0.3-2.0)	0.8 (0.4-2.8)	NS
Cholinesterase (U/L)
At month 1	3681.3 ± 1354.3	4403.9 ± 1323.6	NS
At month 3	5996.7 ± 1619.4	6830.7 ± 1750.5	NS
At month 6	7255.4 ± 1662.9	7171.5 ± 1721.6	NS
Hypertriglyceridemia n (%)	9 (56.3)	12 (12.1)	< 0.001
Hypercholesterolemia n (%)	3 (18.8)	9 (9.1)	NS
PTHL n (%)	9 (56.3)	19 (19.2)	0.003

Hypertriglyceridemia was defined as serum triglycerides ≥ 150 mg/dL; Hypercholesterolemia was defined as serum cholesterol ≥ 200mg/dL. PTHL: Post-transplant hyperlipidemia; MELD: Model for end-stage of liver disease; ERD: Early renal dysfunction; NS: Not significant.